Pfizer Symbiq Infusion System
Approved changes feed: RSS · Atom
cpe:2.3:h:pfizer:symbiq_infusion_system:-:*:*:*:*:*:*:*
part: h version: - update: *
| Vendor | Pfizer (b3fbfd04-13a5-5881-89c1-b54f433c32d8) |
|---|---|
| Product | Symbiq Infusion System (97959692-b293-5511-97fa-25e2e4986636) |
| Edition | * |
| Language | * |
| Software edition | * |
| Target software | * |
| Target hardware | * |
| Other | * |
| Notes | Imported from NVD CPE 2.0 feed |
PURL mappings
| PURL | Source | Last updated |
|---|---|---|
| No PURL mappings for this CPE yet. | ||
Vulnerability references
| Identifier | cpeApplicability | Submitted | db.gcve.eu details | Rationale |
|---|---|---|---|---|
CVE:CVE-2015-3965 |
not_vulnerable | 2026-06-08 05:06:38.906042 |
Details available
Hospira Symbiq Infusion System 3.13 and earlier allows remote authenticated users to trigger "unanticipated operations" by leveraging "elevated privileges" for an unspecified call to an incorrectly exposed function.
Published: 2019-03-23T19:23:49.000Z
Updated: 2024-08-06T06:04:02.807Z Reference links |
Imported from gcve-enriched-dumps CVE data |
Contribute
You can submit an edit proposal for this CPE entry or suggest a related product/vendor addition using the action button above.